Randomisation

Randomisation is clearly a key element in the design of our clinical trials. There are two reasons why we randomise subjects to the treatment groups [Pg.4]

Randomisation lists are produced in a variety of ways and we will discuss several methods later. Once the list is produced the next patient entering the trial receives the next allocation within the randomisation scheme. In practice this process is managed by packaging the treatments according to the pre-defined randomisation list. [Pg.4]

There are a number of different possibilities when producing randomisation lists [Pg.4]

Uncontrolled Variables and Randomization. A number of further variables, such as ambient conditions (temperature, pressure, etc), can be identified but not controlled, or are only ha2ily identified or not identified at all but affect the results of the experiment. To ensure that such uncontrolled variables do not bias the results, randomisation is introduced in various ways into the experiment to the extent that this is practical. [Pg.521]

For some applieations it is desirable that the fluids be free from the volatile low molecular products that result from the randomising equilibration reaction. This operation may be earned out either batchwise or continuously using a vacuum still. Commercial non-volatile fluids have a weight loss of less than 0.5% after 24 hours at 150°C. [Pg.824]

Antiplatetelet Trialists Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 71-86... [Pg.171]

Cannon CP, Curtis SP, FitzGerald GA et al (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme a randomised comparison. Lancet 368 1771-1781... [Pg.407]

Wallenborn J, Gelbrich G, Bulst D et al (2006) Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone randomised double blind multicentre trial. Br Med J 333 324-327... [Pg.462]

Cholesterol Treatment Trialists (CTT) Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 1267-1278... [Pg.599]

Please describe the unit of randomisation, how the allocation schedule was devised and the method of execufion of the randomisation process. [Pg.84]

PD 020 Vol. 6, Bridging study Randomised Tablet, 50 mg. 24 (12 drug. Patients with 2 weeks Ongoing ... [Pg.108]

Efficaqf 035 Vol. 10, Long term Efficacy Randomised Tablet, 50 mg. 300 (152 test Patients with 48 weeks Complete ... [Pg.108]

Johnson BA, Ait-Daoud N, Bowden CL, et al Oral topiramate for rrearment of alcohol dependence a randomised conrrolled trial. Lancet 361 1677—1685, 2003 June HL, Foster KL, McKay PF, er al The reinforcing properties of alcohol are mediared hy GABAj j receptors in rhe venrral pallidum. Neuropsychopharmacology... [Pg.47]

Oude Voshaar RC, Gorgels WJ, Mol AJ, et al Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy three-condition, randomised controlled trial. Br J Psychiatry 182 498-304, 2003 Parry HJ, Balter MB, Mellinger GD, et al National patterns of psychotherapeutic drug use. Arch Gen Psychiatry 28 18-74, 1973... [Pg.158]

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomised trial. Lancet 358 958-965... [Pg.23]

Poynard T, MarceUin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352 1426-1432... [Pg.239]

Kim SW, Moon SE, Kim JA, Eun HC (1999) Glycolic acid versus Jessner s solution which is better for facial acne patients A randomised prospective clinical trial of split-face model therapy. Dermatol Surg 25(4) 270-273... [Pg.21]

Bellomo R. Chapman M, Finfer S, Hickhng K, Myburth J Low-dose dopamine in patients with early renal dysfunction a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Chnical Trials Group. Lancet 2000 356 2139-2143. [Pg.208]

Lorenz W Duda D, Dick W Sitter H, Doenicke A, Black A, Weber D, Menke H, Stinner B, Junginger T, Rothmund M, Ohmann CH, Healy MJ Incidence and clinical importance of perioperative histamine release randomised study of volume loading and antihistamines after induction of anaesthesia. Lancet 1994 343 933-940. [Pg.209]

Hamilton SH, Revicki DA, Edgell ET, et al (1999). Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia results from a randomised clinical trial. Pharmacoeconomics 15, 469—80. [Pg.40]

Simon G, Wagner E, VonKorff M (1995b). Cost-effectiveness comparisons using Real World randomised trials the case of new antidepressant drugs. J Clin Epidemiol4, 363-73. [Pg.54]

Bowden CL, Calabrese JR, McElroy SL, et al (2000). A randomised, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 57, 481—9. [Pg.76]

Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group (1998). A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild and moderately severe Alzheimer s disease. IntJGeriatrPsychopharmacolX, 55-65. [Pg.86]

Rogers SL, Friedhoff LT (1996). The efficacy and safety of Donepezil in patients with Alzheimer s disease results of a US multicentre, randomised, double-blind, placebo-controlled trial. Dementia ,... [Pg.87]

See also in sourсe #XX -- [ Pg.4 , Pg.5 , Pg.6 , Pg.7 , Pg.8 , Pg.9 , Pg.10 , Pg.250 ]

See also in sourсe #XX -- [ Pg.78 ]

See also in sourсe #XX -- [ Pg.4 , Pg.153 ]

See also in sourсe #XX -- [ Pg.78 ]

See also in sourсe #XX -- [ Pg.32 ]

See also in sourсe #XX -- [ Pg.141 , Pg.145 , Pg.202 ]

See also in sourсe #XX -- [ Pg.178 ]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...